April 1, 2019
Off
Poxel Initiates Phase 2a Program for PXL770, a Direct AMPK Activator for the Treatment of NASH
By BusinessWireThe Phase 2a program will include two separate studies Phase 2a efficacy and safety study for PXL770 is underway with…